Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,359 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06885814RecruitingPhase 2
Adebrelimab with chemoradiation for advanced esophageal cancer
This trial tests a drug called adebrelimab (an immunotherapy) combined with chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery or has come back after surgery. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06886516RecruitingEarly Phase 1
Blood thinner study for cancer patients with low platelets
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
Boston, MassachusettsAges 18 years+ - NCT06888921RecruitingPhase 1/Phase 2
COM701 for platinum-sensitive ovarian cancer
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
Augusta, GeorgiaAges 18 years+ - NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06902272RecruitingPhase 2
Blood test to predict chemo-immunotherapy response in lung cancer
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
Miami, FloridaAges 18 years+ - NCT06903325Recruiting
Monitoring DNA markers in blood to predict colorectal cancer return after surgery
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT06912711RecruitingPhase 2
Chemo before and after surgery for recurrent nasal cancer
This trial tests giving chemotherapy before and after surgery for people whose nasal cancer has come back. The goal is to see if this approach helps remove the cancer more effectively and prevents it from returning again.
Guangzhou, GuangdongAges 18–65 - NCT06917573RecruitingPhase 2
Cemiplimab for advanced lung cancer with high PD-L1
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Alicante, AlicanteAges 18 years+ - NCT06921837RecruitingPhase 1/Phase 2
BDC-4182 for advanced gastric or gastroesophageal cancer
This trial tests a new drug called BDC-4182 for advanced gastric or gastroesophageal cancer. It is for people who have already tried standard treatments and may target a protein called Claudin 18 on some cancer cells.
Darlinghurst, New South WalesAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06923761RecruitingPhase 1/Phase 2
Trial of a new drug for advanced solid tumors
This trial tests a new drug (GRWD5769) that may help your immune system fight cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including certain types of cervical, liver, and other cancers.
AdelaideAges 18 years+ - NCT06923826RecruitingPhase 2
Study of sacituzumab govitecan for advanced salivary gland and thyroid cancers
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
SingaporeAges 21 years+ - NCT06925061RecruitingPhase 2
Testing EXL01 to prevent Crohn's disease return after surgery
This study tests a new oral treatment called EXL01 to see if it can prevent Crohn's disease from coming back after surgery to remove part of the small and large intestine. It may be an option if you are not planning to use strong immune-suppressing drugs (except anti-TNF) in the next 6 months.
Clermont-FerrandAges 18 years+ - NCT06926075RecruitingPhase 1/Phase 2
Early trial of KESONOTIDE™ for solid tumors
This trial tests a new tablet called KESONOTIDE™ for people with solid tumors that have spread. The goal is to see if it can help when other treatments have stopped working or are not an option.
Kogarah, New South WalesAges 18 years+ - NCT06926374Recruiting
Robotic surgery for gastrointestinal and urologic conditions
This trial tests a new robotic surgery system for common operations on the colon, rectum, prostate, kidney, bladder, stomach, esophagus, gallbladder, and hiatal hernia. It may offer a less invasive option for patients who need surgery for these conditions.
Hong KongAges 18–80 - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06941363Recruiting
Salvage radiotherapy for prostate cancer recurrence after surgery
This study tests a very short course of radiation given after prostate surgery, specifically for men whose PSA is rising again. The goal is to see if this approach can safely control the cancer.
Monza, ItalyAges 18–90 - NCT06948786RecruitingPhase 2
Pirtobrutinib and Mosunetuzumab for relapsed follicular lymphoma
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Seattle, WashingtonAges 18 years+ - NCT06952868RecruitingPhase 2
BNCT for recurrent head and neck cancer
This trial tests a special type of radiation therapy called BNCT (boron neutron capture therapy) for head and neck cancers that have come back and cannot be removed by surgery. It may be an option for patients who have already had radiation and cannot receive standard chemotherapy.
TaichungAges 18–80 - NCT06953999RecruitingPhase 3
Testing immunotherapy plus chemo for metastatic pancreatic cancer
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Harbin, HeilongjiangAges 18–75 - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06954610Recruiting
Heart Check for Stroke Risk in Atrial Fibrillation
This trial uses heart imaging to better understand stroke risk in people with atrial fibrillation (an irregular heartbeat). It may help doctors decide on the best treatment to prevent another stroke.
BernAges 18 years+ - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,359 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.